Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - ticagrelor (unii: glh0314rvc) (ticagrelor - unii:glh0314rvc) - ticagrelor tablets are indicated to reduce the risk of cardiovascular death, myocardial infarction (mi), and stroke in patients with acute coronary syndrome (acs) or a history of mi. for at least the first 12 months following acs, it is superior to clopidogrel. ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of acs [see clinical studies (14.1)] . ticagrelor tablets are indicated to reduce the risk of a first mi or stroke in patients with coronary artery disease (cad) at high risk for such events [see clinical studies (14.2)]. while use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (t2dm). ticagrelor tablets are contraindicated in patients with a history of intracranial hemorrhage (ich) because of a high risk of recurrent ich in this population [see clinical studies (14.1), (14.2)] . ticagrelor tablets are contraindicated in patients with active pathological bleeding

Canada - English - Health Canada

apotex inc - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors

Canada - English - Health Canada

angita pharma inc. - ticagrelor - tablet - 60mg - ticagrelor 60mg

Canada - English - Health Canada

mantra pharma inc - ticagrelor - tablet - 90mg - ticagrelor 90mg

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - ticagrelor (unii: glh0314rvc) (ticagrelor - unii:glh0314rvc) - ticagrelor 90 mg - brilinta is indicated to reduce the risk of cardiovascular (cv) death, myocardial infarction (mi), and stroke in patients with acute coronary syndrome (acs) or a history of mi. for at least the first 12 months following acs, it is superior to clopidogrel. brilinta also reduces the risk of stent thrombosis in patients who have been stented for treatment of acs [see clinical studies (14.1)] . brilinta is indicated to reduce the risk of a first mi or stroke in patients with coronary artery disease (cad) at high risk for such events [see clinical studies (14.2)] . while use is not limited to this setting, the efficacy of brilinta was established in a population with type 2 diabetes mellitus (t2dm). brilinta is indicated to reduce the risk of stroke in patients with acute ischemic stroke (nih stroke scale score ≤5) or high-risk transient ischemic attack (tia) [see clinical studies (14.3)] . brilinta is contraindicated in patients with a history of intracranial hemorrhage (ich) because of a high risk of recurrent i

Canada - English - Health Canada

taro pharmaceuticals inc - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors

Malta - English - Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - ticagrelor - film-coated tablet - ticagrelor 90 mg - antithrombotic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; mannitol; calcium hydrogen phosphate dihydrate; purified water; hyprolose; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - ticagrelor, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).